$RPHM
Reneo Pharmaceuticals Inc

2021 Q2 Form 10-Q Financial Statement

#000155837021007568 Filed on May 20, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.949M $1.742M $920.0K
YoY Change 235.11% 89.35%
% of Gross Profit
Research & Development $6.279M $5.472M $3.578M
YoY Change 122.9% 52.93%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $9.000K
YoY Change 11.11% 11.11%
% of Gross Profit
Operating Expenses $9.228M $7.214M $4.502M
YoY Change 149.47% 60.24%
Operating Profit -$9.228M -$7.214M -$4.502M
YoY Change 149.47% 60.24%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $12.00K $2.000K $70.00K
YoY Change 20.0% -97.14%
Pretax Income -$9.216M -$7.212M -$4.430M
YoY Change 149.76% 62.8%
Income Tax
% Of Pretax Income
Net Earnings -$9.216M -$7.212M -$4.431M
YoY Change 149.96% 62.76%
Net Earnings / Revenue
Basic Earnings Per Share -$3.48
Diluted Earnings Per Share -$431.4K -$3.48 -$0.18
COMMON SHARES
Basic Shares Outstanding 24.29M 2.071M
Diluted Shares Outstanding 2.071M

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $167.3M $91.22M
YoY Change
Cash & Equivalents $140.4M $91.20M $18.28M
Short-Term Investments $26.96M
Other Short-Term Assets $3.810M $2.339M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $171.1M $93.56M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $85.00K $81.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $78.00K $1.680M
YoY Change
Total Long-Term Assets $163.0K $1.761M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $171.1M $93.56M
Total Long-Term Assets $163.0K $1.761M
Total Assets $171.3M $95.32M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $434.0K $556.0K
YoY Change
Accrued Expenses $2.902M $3.374M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.336M $3.930M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $417.0K $32.00K
YoY Change
Total Long-Term Liabilities $417.0K $32.00K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.336M $3.930M
Total Long-Term Liabilities $417.0K $32.00K
Total Liabilities $3.753M $3.962M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$61.40M -$97.80M
YoY Change
Common Stock $3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $167.6M -$48.72M -$27.43M
YoY Change
Total Liabilities & Shareholders Equity $171.3M $95.32M
YoY Change

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$9.216M -$7.212M -$4.431M
YoY Change 149.96% 62.76%
Depreciation, Depletion And Amortization $10.00K $10.00K $9.000K
YoY Change 11.11% 11.11%
Cash From Operating Activities -$9.701M -$8.589M -$4.447M
YoY Change 231.09% 93.14%
INVESTING ACTIVITIES
Capital Expenditures -$6.000K $25.00K $1.000K
YoY Change 2400.0%
Acquisitions
YoY Change
Other Investing Activities -$26.99M $0.00 $5.200M
YoY Change -2798.9% -100.0%
Cash From Investing Activities -$27.00M -$25.00K $5.199M
YoY Change -2799.5% -100.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $187.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 85.84M 46.22M 26.00K
YoY Change 177676.92%
NET CHANGE
Cash From Operating Activities -9.701M -8.589M -4.447M
Cash From Investing Activities -27.00M -25.00K 5.199M
Cash From Financing Activities 85.84M 46.22M 26.00K
Net Change In Cash 49.15M 37.61M 778.0K
YoY Change -2646.48% 4733.93%
FREE CASH FLOW
Cash From Operating Activities -$9.701M -$8.589M -$4.447M
Capital Expenditures -$6.000K $25.00K $1.000K
Free Cash Flow -$9.695M -$8.614M -$4.448M
YoY Change 230.89% 93.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.712
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8589000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2053070
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001637715
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2235
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Assets
Assets
95321000
CY2020Q4 us-gaap Liabilities
Liabilities
4616000
CY2021Q1 dei Entity File Number
EntityFileNumber
001-40315
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Reneo Pharmaceuticals, Inc.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2309515
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
12230 El Camino Real, Suite 230
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2021Q1 dei City Area Code
CityAreaCode
858
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
283-0280
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
RPHM
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24286253
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91221000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53613000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2339000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1412000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
93560000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
55025000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
81000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1680000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
127000
CY2020Q4 us-gaap Assets
Assets
55221000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
556000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
908000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3374000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3672000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3930000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4580000
CY2021Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
32000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
36000
CY2021Q1 us-gaap Liabilities
Liabilities
3962000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
105000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
105000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2148193
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2123733
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2053070
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3453000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2843000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52170000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44958000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-48717000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-42115000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95321000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55221000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5472000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3578000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1742000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
924000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
7214000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
4502000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7214000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4502000
CY2021Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2000
CY2020Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
71000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7212000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4431000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7212000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4425000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.48
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.20
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2070935
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2015029
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-42115000
CY2021Q1 rphm Temporary Equity Issuance Costs
TemporaryEquityIssuanceCosts
29000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
471000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7212000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-48717000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-23127000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
92000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4431000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-27434000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7212000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4431000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
15000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
471000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
92000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-927000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
36000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
929000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
137000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8600000
CY2021Q2 rphm Proceeds For Initial Public Offering Net
ProceedsForInitialPublicOfferingNet
84800000
CY2021Q1 rphm Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-2000
CY2020Q1 rphm Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-1000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4447000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
5200000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5199000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
187000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
26000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1223000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46222000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37608000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
778000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53613000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17501000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91221000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18279000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000
CY2021Q1 rphm Unpaid Convertible Preferred Stock Issuance Costs
UnpaidConvertiblePreferredStockIssuanceCosts
19000
CY2021Q1 rphm Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
361000
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On April 5, 2021, the Company effected a 1-for-4.4748 reverse stock split of its common stock. The par value and the authorized number of shares of the common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the Series A and Series B convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying condensed consolidated financial statements and notes to the condensed consolidated financial statements give retroactive effect to the reverse stock split for all periods presented.
CY2021Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
146700000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91200000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52200000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7200000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure in the Company’s condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></p>
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19021269
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6407087
CY2021Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
89563000
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
93000
CY2020Q1 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2021Q1 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
83000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
81000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
49632000
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
322000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3374000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3672000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.716
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
174000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
152000
CY2021Q1 rphm Accrued Development Expenses
AccruedDevelopmentExpenses
1159000
CY2020Q4 rphm Accrued Development Expenses
AccruedDevelopmentExpenses
1443000
CY2021Q1 rphm Accrued Clinical Expenses
AccruedClinicalExpenses
997000
CY2020Q4 rphm Accrued Clinical Expenses
AccruedClinicalExpenses
1019000
CY2021Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
514000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
888000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
704000
CY2021Q1 rphm Temporary Equity Dividend Rate Percentage
TemporaryEquityDividendRatePercentage
0.08
CY2021Q1 rphm Number Of Convertible Shares Converted Into Common Stock
NumberOfConvertibleSharesConvertedIntoCommonStock
1
CY2021Q1 rphm Minimum Specified Amount Of Proceeds From Public Offering
MinimumSpecifiedAmountOfProceedsFromPublicOffering
75000000
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.15
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19138871
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
935478
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.56
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2273285
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.06
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
95123
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.97
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
418000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3113640
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.41
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6086000
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
615517
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2.49
CY2021Q1 rphm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P7Y4M24D
CY2021Q1 rphm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue
2384000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2772210
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.40
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y2M12D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5441000
CY2021Q1 us-gaap Share Price
SharePrice
6.36
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0066
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0144
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.40
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7200000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
471000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
92000
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
46000000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
46000000

Files In Submission

Name View Source Status
0001558370-21-007568-index-headers.html Edgar Link pending
0001558370-21-007568-index.html Edgar Link pending
0001558370-21-007568.txt Edgar Link pending
0001558370-21-007568-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rphm-20210331.xsd Edgar Link pending
rphm-20210331x10q.htm Edgar Link pending
rphm-20210331x10q004.jpg Edgar Link pending
rphm-20210331x10q_htm.xml Edgar Link completed
rphm-20210331xex31d1.htm Edgar Link pending
rphm-20210331xex31d2.htm Edgar Link pending
rphm-20210331xex32d1.htm Edgar Link pending
rphm-20210331xex32d2.htm Edgar Link pending
rphm-20210331_cal.xml Edgar Link unprocessable
rphm-20210331_def.xml Edgar Link unprocessable
rphm-20210331_lab.xml Edgar Link unprocessable
rphm-20210331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending